(Q54632156)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Li Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jie Li

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ya-Li Lv

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Qiong Sun

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ling-Xiong Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Shun-Chang Jiao

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

18 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

381-390

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s13277-010-0131-8

16 January 2020

exact match

0 references

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

MAP kinase signalling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Involvement of Akt1/protein kinase Balpha in tumor conditioned medium-induced endothelial cell migration and survival in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Biomarkers to predict response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-010-0131-8

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation

21 January 2018

1 reference

12 December 2020

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathwa

1 reference

12 December 2020

Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells.

1 reference

12 December 2020

Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance

1 reference

12 December 2020

BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer

1 reference

12 December 2020

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

12 December 2020

Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage

1 reference

12 December 2020

Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC)

1 reference

12 December 2020

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

1 reference

12 December 2020

10.1007/S13277-010-0131-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21086091%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference